Could a common arthritis drug help people with down syndrome think and learn better?

NCT ID NCT07598643

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether tofacitinib, a drug used for arthritis, can improve thinking skills and immune function in people with Down syndrome aged 6 to 22. Half of the 92 participants will receive the drug for 6 months, and the other half a placebo. Researchers will measure changes in intelligence, attention, and daily living skills, while closely watching for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tofacitinib (XELJANZ), a JAK inhibitor drug
What this could lead to: If successful, this could point toward a treatment that improves thinking, learning, and overall health in people with Down syndrome.
What could go wrong: This is an early phase 2 trial with only 92 participants, so results may not apply to everyone. The drug also carries risks like infection and requires careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DOWN SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Down syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DOWN SYNDROME

Contacts and locations

Show contact details

Locations

CU Anschutz, Children's Hospital Colorado
RECRUITING

Aurora, Colorado, 80045, United States

Contact Email: •••••@•••••

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.